MCID: NSP003
MIFTS: 25

Nasopharyngeal Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasopharyngeal Disease

MalaCards integrated aliases for Nasopharyngeal Disease:

Name: Nasopharyngeal Disease 12 15
Nasopharyngeal Diseases 56 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9561
MeSH 45 D009302
NCIt 51 C35723
UMLS 74 C0027438

Summaries for Nasopharyngeal Disease

MalaCards based summary : Nasopharyngeal Disease, also known as nasopharyngeal diseases, is related to nasopharyngitis. An important gene associated with Nasopharyngeal Disease is PSMB9 (Proteasome Subunit Beta 9). The drugs Erythromycin and Nimotuzumab have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and colon.

Related Diseases for Nasopharyngeal Disease

Diseases related to Nasopharyngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 nasopharyngitis 11.1

Symptoms & Phenotypes for Nasopharyngeal Disease

Drugs & Therapeutics for Nasopharyngeal Disease

Drugs for Nasopharyngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
2
Nimotuzumab Investigational Phase 4,Phase 3,Phase 2 780758-10-3, 828933-61-3
3 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Erythromycin stearate Phase 4
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Erythromycin Estolate Phase 4
7 Erythromycin Ethylsuccinate Phase 4
8 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
19
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
20
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
21
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
22
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
23
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
24
Hydroxyurea Approved Phase 3,Phase 1 127-07-1 3657
25
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 3 128-13-2 31401
26
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
27
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
28
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
29
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 154361-50-9 60953
30
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
31
Sulindac Approved, Investigational Phase 3,Phase 2 38194-50-2 1548887 5352
32
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
33
Budesonide Approved Phase 3,Not Applicable 51333-22-3 5281004 63006
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
36
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
37
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
38
Amifostine Approved, Investigational Phase 3,Phase 2 20537-88-6 2141
39
Epirubicin Approved Phase 3 56420-45-2 41867
40
Oprelvekin Approved, Investigational Phase 3 145941-26-0
41
mometasone furoate Approved, Investigational, Vet_approved Phase 3,Phase 2 83919-23-7
42 Benralizumab Approved, Investigational Phase 3 1044511-01-4
43
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
44
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
45
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
46
Acyclovir Approved Phase 3 59277-89-3 2022
47
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
48
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
49
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
50
Serine Approved, Nutraceutical Phase 3 56-45-1 5951

Interventional clinical trials:

(show top 50) (show all 455)
# Name Status NCT ID Phase Drugs
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
2 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
6 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
7 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Unknown status NCT03006588 Phase 2, Phase 3
8 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
9 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
10 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
11 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
12 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
13 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
14 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
15 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
16 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
17 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
18 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
19 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
20 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
21 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
22 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
23 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
24 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
25 Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis. Completed NCT03687515 Phase 3 budesonide;budesonide;Prednisone
26 Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma Completed NCT02137096 Phase 3 Etoposide phosphate;Carboplatin;Ifosfamide
27 Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC Completed NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
28 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety Completed NCT01622569 Phase 3 Fluticasone Propionate
29 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
30 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
31 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Completed NCT01197612 Phase 3 pulmicort
32 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
33 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
34 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
35 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
36 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
37 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
38 GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT03840421 Phase 3 gemcitabine and cisplatin;cisplatin and fluorouracil;cisplatin
39 Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma Recruiting NCT03837808 Phase 3 Nimotuzumab;Cisplatin
40 Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT03919552 Phase 3 Docetaxel,Carboplatin;Docetaxel,Cisplatin
41 Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma Recruiting NCT03908372 Phase 2, Phase 3 Docetaxel;Cisplatin
42 Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis Recruiting NCT03806426 Phase 3 Eicosapentaenoic acid free fatty acid (EPA-FFA);Placebo
43 Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma(NPC) Patients Treated With Combined Radio-Chemotherapy Recruiting NCT03720340 Phase 3 Recombinant Human Interleukin-11;Saline
44 Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Recruiting NCT03707509 Phase 3 Camrelizumab;Placebos;Gemcitabine;Cisplatin
45 GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Recruiting NCT03604965 Phase 3 GP+CCRT;TPF+CCRT
46 Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Recruiting NCT03601975 Phase 3 Gemcitabine/Cisplatin
47 TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Recruiting NCT03574324 Phase 3 TPF+CCRT;CCRT+PF
48 Adjuvant PD-1 Antibody in Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy Recruiting NCT03427827 Phase 3 PD-1 antibody
49 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
50 Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis Recruiting NCT03401229 Phase 3

Search NIH Clinical Center for Nasopharyngeal Disease

Cochrane evidence based reviews: nasopharyngeal diseases

Genetic Tests for Nasopharyngeal Disease

Anatomical Context for Nasopharyngeal Disease

MalaCards organs/tissues related to Nasopharyngeal Disease:

42
Brain, Liver, Colon, Bone, Nk Cells, Tongue, T Cells

Publications for Nasopharyngeal Disease

Articles related to Nasopharyngeal Disease:

# Title Authors Year
1
Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases. ( 26662436 )
2015
2
Expression of GRIN2A in benign and malignant nasopharyngeal diseases and its clinical significance. ( 26681223 )
2015
3
Nasopharyngeal disease in cats: 1. Diagnostic investigation. ( 22511473 )
2012
4
Nasopharyngeal disease in cats: 2. Specific conditions and their management. ( 22511474 )
2012
5
Nasopharyngeal diseases in cats: a retrospective study of 53 cases (1991-1998). ( 10580903 )
1999
6
Management of some benign nasopharyngeal diseases in the adult; supplementary report. ( 13356856 )
1956
7
Surgical treatment of benign nasopharyngeal disease in the adult. ( 14943338 )
1952
8
A new pharyngoscope; facilitating diagnosis and treatment of nasopharyngeal diseases. ( 20994675 )
1946

Variations for Nasopharyngeal Disease

Expression for Nasopharyngeal Disease

Search GEO for disease gene expression data for Nasopharyngeal Disease.

Pathways for Nasopharyngeal Disease

GO Terms for Nasopharyngeal Disease

Sources for Nasopharyngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....